Melanoma

 

  • ECOG E3612– A Phase II Randomized Study of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • SWOG S1320– A Phase II Randomized Study of Intermittent Versus Continous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma (Temporarily closed due to drug supply issues)
  • ECOG-ACRIN EA6134– A Phase III Randomized Study of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma (Temporarily closed due to drug supply issues)
  • ECOG-ACRIN EA6141– A Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • SWOG S1404– A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma